drugset

drugset / Trial / NCT05213195

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

NCT05213195 ↗

Phase 1 Unknown 38 enrolled Zhejiang University

NaSequentialOpen-labelTreatment

Summary

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

Timeline

Start: 2021-12-10
Primary completion: 2024-12-31
Completion: 2025-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NKG2D CAR-NK	Cell therapy	—	Other

Indications